Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation.
Saved in:
| Title: | Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. |
|---|---|
| Authors: | Cardona-Benavides IJ; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., Cristobal-Vargas S; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., De Ramón C; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., Rojas EA; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., Misiewicz-Krzeminska I; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Isidro I; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., Pérez JJ; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain., Paiva B; Clínica Universidad de Navarra, Centro de Investigaciones Biomédicas Aplicadas (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Puig N; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Alcoceba M; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mateos MV; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Corchete LA; Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cuadrado M; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain., Gutiérrez NC; Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. |
| Source: | Molecular oncology [Mol Oncol] 2025 Nov; Vol. 19 (11), pp. 3175-3192. Date of Electronic Publication: 2025 Jul 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
